Detecting these two oncogenic driver mutations has become essential in the treatment of NSCLC, specifically adenocarcinoma [6], as both mutations are sensitive to drugs that target EGFR [2], and screening for these mutations predict which patients will respond to therapy [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.